LifeSci Capital analyst Anshul Dhankher maintained a Buy rating on Aura Biosciences Inc (AURA - Research Report) today and set a price target of $23.00.

Anshul Dhankher's rating is based on promising early clinical data for Aura Biosciences' AU-011 treatment in non-muscle invasive bladder cancer (NMIBC). The Phase 1 study results indicated a favorable safety profile and initial signs of efficacy, with several patients showing complete clinical responses and tumor shrinkage. The treatment's dual mechanism of action, which includes both direct tumor cell destruction and an immune response activation, is a key factor in its potential effectiveness.

Moreover, the study's findings provide a positive early signal for the continued development of AU-011, not only in bladder cancer but also in ocular oncology. The infiltration of immune cells observed in both treated and neighboring tumors supports the treatment's broader applicability. These promising clinical outcomes, along with the company's current financial position, contribute to Dhankher's Buy rating for Aura Biosciences Inc.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AURA in relation to earlier this year.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.